Repligen Co. (NASDAQ:RGEN) Position Raised by Ballentine Partners LLC

Ballentine Partners LLC lifted its stake in shares of Repligen Co. (NASDAQ:RGEN) by 4.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,879 shares of the biotechnology company’s stock after acquiring an additional 72 shares during the quarter. Ballentine Partners LLC’s holdings in Repligen were worth $270,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Champlain Investment Partners LLC grew its stake in Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after purchasing an additional 850,345 shares in the last quarter. DF Dent & Co. Inc. grew its stake in Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Repligen by 39.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after purchasing an additional 121,305 shares during the period. Two Sigma Advisers LP grew its stake in shares of Repligen by 421.9% in the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after acquiring an additional 102,100 shares during the last quarter. Finally, Fred Alger Management LLC raised its position in shares of Repligen by 29.5% during the third quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company’s stock valued at $59,313,000 after buying an additional 90,831 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN stock opened at $165.89 on Friday. The company has a market cap of $9.29 billion, a P/E ratio of -448.34, a P/E/G ratio of 4.51 and a beta of 0.97. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a 50-day moving average of $150.83 and a 200-day moving average of $146.05. Repligen Co. has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter last year, the business earned $0.23 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. Equities research analysts forecast that Repligen Co. will post 1.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. HC Wainwright decreased their target price on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research report on Thursday. Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Finally, Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $184.73.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.